Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment
| Autor: | Grigorios T. Sakellariou, Panagiotis Kokkoris, Evangelos Terpos, Matthaios Savvidis, Stergios A. Polyzos, Polyzois Makras, Athanasios D. Anastasilakis, Athanasios Papatheodorou, Athina Gkiomisi |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Clinical Biochemistry Osteoporosis Nerve Tissue Proteins Receptors Cell Surface Semaphorins Antibodies Monoclonal Humanized Zoledronic Acid N-terminal telopeptide Antigens CD Bone Density Internal medicine Teriparatide Drug Discovery medicine Humans Vitamin D Osteoporosis Postmenopausal Aged Pharmacology Postmenopausal women Lumbar Vertebrae Bone Density Conservation Agents Diphosphonates business.industry Imidazoles Bisphosphonate Middle Aged medicine.disease Denosumab Zoledronic acid Endocrinology Parathyroid Hormone Case-Control Studies Molecular Medicine Female business Body mass index medicine.drug |
| Zdroj: | Expert opinion on therapeutic targets. 19(3) |
| ISSN: | 1744-7631 |
| Popis: | The evaluation of circulating semaphorin-4D (sema4D) and plexin-B1 in postmenopausal women with low bone mass and the effect of antiresorptive or osteoanabolic treatment.Serum samples were obtained from postmenopausal women with low bone mass at baseline and 3 months after zoledronic acid infusion (n = 30), denosumab injection (n = 30) or teriparatide initiation (n = 28) and from controls matched for age, age at menopause and body mass index (n = 30) at the same time points.Circulating sema4D and plexin-B1.Circulating sema4D increased following denosumab (p = 0.026), whereas decreased following teriparatide (p = 0.013). Sema4D/plexin-B1 ratio increased following denosumab (p = 0.004). At baseline, sema4D and plexin-B1 levels were higher in patients pre-treated with bisphosphonates compared to naïve ones (p0.001 and p = 0.001, respectively). In bivariate correlations sema4D was inversely correlated with serum carboxyterminal telopeptide of type 1 collagen (rs -0.282, p = 0.002), intact parathyroid hormone (rs -0.388, p0.001) and 25(OH)D (rs -0.316, p0.001), whereas there was a trend towards correlation with lumbar spine bone mineral density (rs -0.191, p = 0.053).Sema4D levels are independently associated with previous bisphosphonate treatment, intact parathyroid hormone and 25(OH)D levels. Denosumab and teriparatide seem to exert an opposite effect on circulating sema4D levels. Further studies are needed to evaluate whether sema4D mediates the coupling effect that occurs following both antiresorptive and osteoanabolic treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|